BY MIKKEL AABENHUS HEMMINGSEN
-
Novo Nordisk says Ozempic “very likely” target for next US price cut
Novo President Lars Fruergaard Jørgensen will certainly indicate prior to an Us senate board led by Legislator Bernie Sanders concerning the medicines’ rates following week.
-
Pfizer drug helped cancer patients regain weight, study shows
The medicine was uncovered internal at Pfizer.
-
New chairman for EMA’s Committee for Orphan Medicinal Products
His precursor will certainly tip down after offering the optimum 6 years.
-
Demant appoints replacement for laid-off Executive
The brand-new exec will certainly take control of duty for Demant’s diagnostics company and sign up with the administration group.
-
WS Audiology appoints new General Counsel
She’s going to be a part of the WSA on October 21, 2024
-
Novo Holdings invests again in antifungal agent
The major possession belongs to an entire brand-new course of antifungal medicines.
-
Zepbound helped type 1 diabetes patients lose weight in study
Zepbound surpassed Novo Nordisk’s Ozempic, with individuals taking that shot.
-
The FDA has granted Ascendis Orphan Drug exclusivity in the United States
The medicine Yorvipath can not be tested in the United States for the following 7 years.
-
Lilly bulks up European manufacturing in obesity drug push
” When we saw Wegovy launch, no one forecasted that, so we altered all our numbers,” Eli Lilly chief executive officer David Ricks claimed in a meeting.
-
GSK stops herpes vaccine trial following clinical setback
Nevertheless, in the statement, GSK specifies that it still sees a requirement for brand-new therapies for herpes.
